Why the study?
Does valsartan prevent angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells?
Does valsartan prevent angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells?
Valsartan effectively inhibits angiotensin II-induced PAI-1 secretion in arterial smooth muscle cells without affecting tPA, suggesting a mechanism for improved fibrinolysis.
No takes yet. Share an insight, caveat, or question.
May support improved fibrinolysis with valsartan; leaves open translation from animal cells to human outcomes.
Sironi et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: